Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

Core Insights - Profound Medical Corp. has introduced new real-world data from the Busch Center, showcasing the effectiveness and versatility of the TULSA Procedure in treating various prostate diseases, marking a significant advancement in prostate care [1][5] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing customizable, AI-powered, incision-free therapies for the ablation of diseased tissue [6][7] TULSA Procedure Details - The TULSA Procedure utilizes a unique incision-free, MRI-guided approach to treat prostate cancer and benign prostatic hyperplasia (BPH), with over 500 procedures completed at the Busch Center [1][2] - The procedure has shown successful outcomes in complex cases, with a significant portion of patients experiencing good cancer control and minimal side effects [2][4] - Approximately 75% of cases at the Busch Center involved customized ablations covering more than 90% of the prostate volume, demonstrating the procedure's adaptability [3] Clinical Outcomes - In a retrospective analysis, the TULSA Procedure resulted in a PSA reduction from 6.7 to 0.9 ng/mL, with 93% of patients showing no evidence of residual disease, while maintaining pad-free continence in 100% of men and erectile function in 82% [4] - The procedure is particularly effective for patients with high-risk disease, utilizing intraoperative MRI guidance and real-time thermography for precision control [3][5] Technology and Innovation - The TULSA-PRO system is the only AI-powered, MRI-guided robotic system for prostate treatment, allowing for real-time visualization and customization of therapy [5][7] - The procedure is designed to be a "one-and-done" treatment, performed in a single session without the need for hospitalization, leading to quick recovery for patients [7] Market Potential - The TULSA Procedure has the potential to become a mainstream treatment for a wide range of prostate diseases, including low-, intermediate-, and high-risk prostate cancer, as well as BPH and salvage therapy for radio-recurrent localized prostate cancer [7]